Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13183208 | 0.93 | HRH4 (0.39) | HRH4POLBKDM4EALDH1A1ALOX15 | |
| SCHEMBL889791 | 0.91 | RAB9A (0.39) | HRH4RAB9APOLBNPC1MAPT | |
| SCHEMBL13783567 | 0.91 | RAB9A (0.39) | HRH4RAB9APOLBNPC1MAPT | |
| SCHEMBL20764182 | 0.88 | HRH4 (0.41) | HRH4POLBKDM4EALDH1A1ALOX15 | |
| SCHEMBL14356126 | 0.87 | RAB9A (0.37) | HRH4RAB9APOLBNPC1MAPT | |
| SCHEMBL20764389 | 0.86 | RAB9A (0.41) | HRH4RAB9APOLBNPC1MAPT | |
| SCHEMBL3494654 | 0.86 | HRH4 (0.35) | HRH4RAB9APOLBNPC1MAPT | |
| SCHEMBL15031239 | 0.85 | RAB9A (0.43) | HRH4RAB9APOLBNPC1MAPT | |
| SCHEMBL20764323 | 0.83 | HRH4 (0.46) | HRH4RAB9APOLBNPC1MEN1 | |
| SCHEMBL888599 | 0.83 | GPR119 (0.39) | HRH4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | HRH4 1343/4885RAB9A 4496/4885POLB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.